ThromboGenics - Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate
(WorldNews Belgium)

ThromboGenics - Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate Resources redirected to progress new drug candidates to clinic in H1 2018 Leuven, Belgium, - ThromboGenics NV (Euronext Brussels: THR), today announces that it has discontinued patient recruitment in its Phase II CIRCLE study for...